OPKO Health to Sell BioReference Testing Assets to Labcorp for $722 Million

Key numbers

Deal value	$722M
Share of market cap	60.1%
Share of annual revenue	119.0%

Key highlights

• Upfront cash consideration of $722 million subject to standard closing revenue adjustments
• Potential for $150 million in additional cash over ten years tied to 4Kscore test revenue
• Divested assets include clinical and women’s health testing, urology, and corrections services
• Termination fee of $28.88 million established if Labcorp fails to obtain HSR Clearance
• Target completion date for the asset transfer set for April 14, 2027

What Is Being Divested?

OPKO Health and its subsidiary BioReference Health have reached a definitive agreement to sell specific clinical and anatomic pathology laboratory testing assets to Laboratory Corporation of America Holdings, known as Labcorp. The $722 million cash transaction encompasses BioReference’s clinical and women’s health testing services, urology, and corrections business. A central component of the sale is the proprietary 4Kscore prostate cancer test. Beyond the initial cash consideration, OPKO remains eligible to receive up to $150 million in additional payments over a ten-year period, contingent upon the revenue performance of the 4Kscore test under Labcorp’s ownership. The deal is expected to close by April 2027.

Why This Divestiture

• Continues a multi-year strategy to streamline the BioReference Health portfolio
• Builds on the March 2025 divestiture of oncology diagnostics to Labcorp for $225 million
• Enables the reallocation of capital toward core biopharmaceutical development programs
• Reduces operational overhead associated with broad-based clinical laboratory infrastructure
• Monetizes the 4Kscore diagnostic platform while retaining long-term financial upside

Financial Impact

The $722 million in upfront proceeds represents a major liquidity event for OPKO Health, providing a cash infusion equivalent to approximately 60% of its current market capitalization. This strengthens the company's financial position following a period where it reported $163.58 million in quarterly revenue. The agreement includes a $28.88 million termination fee, which Labcorp must pay if the transaction is halted due to a failure to secure Hart-Scott-Rodino antitrust clearance. By offloading these clinical assets, OPKO aims to optimize its margin profile by focusing on high-value pharmaceutical products and international operations, moving away from the more capital-intensive domestic testing market.

Business Overview

OPKO Health is a diversified healthcare company active in both the biopharmaceutical and diagnostic sectors. While the company is divesting a significant portion of its domestic clinical testing business, it continues to operate international laboratory services and a robust pharmaceutical division. Its lead product, RAYALDEE, targets secondary hyperparathyroidism in patients with chronic kidney disease. The company also maintains a pipeline focused on metabolic and endocrine disorders. Prior to this divestiture, OPKO had issued 2026 revenue guidance between $560 million and $585 million, reflecting its ongoing transition toward a more specialized medical technology and pharmaceutical model.

Industry Landscape

• Ongoing consolidation trend as national labs acquire regional and specialized testing assets
• Increased focus by diversified healthcare firms on high-margin proprietary medical intellectual property
• Strategic shift among biopharma companies to exit lower-margin diagnostic services
• Growing importance of specialized screening tests like 4Kscore in the oncology diagnostics market

OPKO HEALTH, INC. · financial snapshot

Share price	$1.61
Market cap	$1.2B
Revenue (annual)	$607M
1-month price change	+2.55%
Sector	HealthcareDiagnostics & Research

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.